Skip to main navigation Skip to search Skip to main content

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

  • Guntram Schernthaner
  • , Naim Shehadeh
  • , Alexander S. Ametov
  • , Anna V. Bazarova
  • , Fahim Ebrahimi
  • , Peter Fasching
  • , Andrej Janež
  • , Péter Kempler
  • , Ilze Konrāde
  • , Nebojša M. Lalić
  • , Boris Mankovsky
  • , Emil Martinka
  • , Dario Rahelić
  • , Cristian Serafinceanu
  • , Jan Škrha
  • , Tsvetalina Tankova
  • , Žydrūnė Visockienė
  • Medical University of Vienna
  • Technion-Israel Institute of Technology
  • Russian Ministry of Health
  • Astana Medical University
  • University of Basel
  • St. Claraspital AG
  • Klinik Ottakring
  • University Medical Center Ljubljana
  • Semmelweis University
  • Riga Stradins University
  • Riga East Clinical Hospital
  • University of Belgrade
  • Shupyk National Healthcare University of Ukraine
  • National Institute of Endocrinology and Diabetology
  • Clinical Hospital Merkur
  • University of Zagreb
  • Josip Juraj Strossmayer University of Osijek
  • Carol Davila University of Medicine and Pharmacy
  • Nutrition and Metabolic Diseases
  • Charles University
  • Medical University Sofia
  • Vilnius University

Research output: Contribution to journalArticlepeer-review

130 Scopus citations

Fingerprint

Dive into the research topics of 'Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Keyphrases